Table 5.
Functions of durvalumab in ongoing trials of lung cancer
| Clinical trial information | Phase | Therapy | Disease |
|---|---|---|---|
| Maintenance therapy | |||
| NCT02117167 | II | Durvalumab | Metastatic NSCLC and SD/PR after four cycles of an induction platinum-based chemotherapy |
| NCT02125461 | III | Durvalumab | Stage III unresectable NSCLC and not progressed following definitive, platinum-based, concurrent chemoradiotherapy |
| Neoadjuvant and adjuvant therapy | |||
| NCT02273375 | III | Durvalumab | Completely resected NSCLC |
| NCT02572843 | II | Durvalumab | Primary resectable stage IIIA (N2) NSCLC |
| NCT03030131 | II | Durvalumab | Early stage (I–IIIA) NSCLC |
| First-line therapy | |||
| NCT02879617 | II | Durvalumab | Advanced NSCLC with ECOG performance status of 2 |
| NCT03003962 | III | Durvalumab | Advanced NSCLC with EGFR and ALK wild-type and high expression of PD-L1 |
| NCT03164616 | III | Durvalumab + chemotherapy with/without tremelimumab | Metastatic NSCLC with EGFR and ALK wild-type |
| NCT02453282 | III | Durvalumab with/without tremelimumab | NSCLC |
| NCT02542293 | III | Durvalumab + tremelimumab | NSCLC |
| With radiation therapy | |||
| NCT02888743 | II | Durvalumab + tremelimumab with/without RT | Stage IV NSCLC |
| NCT03275597 | I | Durvalumab + tremelimumab + SBRT | Stage IV oligometastatic NSCLC with EGFR and ALK wild-type |
| Others | |||
| NCT02669914 | II | Durvalumab | Lung cancer with refractory/recurrent brain metastases |
| NCT02352948 | III | Durvalumab with/without tremelimumab | Locally advanced or metastatic NSCLC (stage IIIB–IV) with EGFR and ALK wild-type |
| NCT02403271 | I/II | Durvalumab + ibrutinib | Relapsed or refractory NSCLC |
| NCT02503774 | I | Durvalumab + MEDI9447 | Advanced lung cancer |
| NCT02740985 | I | Durvalumab + AZD4635 | Advanced or metastatic NSCLC with EGFR and ALK wild-type |
| NCT02805660 | I/II | Durvalumab + mocetinostat | Advanced or metastatic NSCLC |
| NCT02898116 | I/II | Durvalumab + ensartinib | ALK-rearranged NSCLC |
| NCT02983578 | II | Durvalumab + AZD9150 | Advanced NSCLC |
| NCT03164772 | I/II | Durvalumab + mRNA vaccine with/without tremelimumab | Metastatic NSCLC with ALK wild-type |
| NCT03334617 | II | Durvalumab + olaparib/AZD9150/AZD6738/vistusertib | Metastatic or recurrent NSCLC with EGFR/ALK/ROS-1 wild-type and progressed on an anti-PD-1/PD-L1 containing therapy |
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; PR, partial response; ROS-1, ROS proto-oncogene 1, receptor tyrosine kinase; RT, radiation therapy; SBRT, stereotactic body radiotherapy; SD, stable disease.